ArticleBMC cancer2024
Comparing supraclavicular surgery with radiotherapy versus radiotherapy alone in breast cancer patients with ipsilateral supraclavicular lymph node metastasis: a two-center retrospective cohort study.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to assess combined supraclavicular lymph node dissection (SLND) and radiotherapy (RT) versus standalone radiotherapy for efficacy in newly diagnosed breast cancer patients with ipsilateral supraclavicular lymph node metastasis (ISLNM).
methodsTotally 143 ISLNM patients treated between 2014 and 2021 in two medical institutions were examined retrospectively. Patients were divided into two groups to undergo combined SLND and radiotherapy (surgery + RT, n = 73) or radiotherapy alone (RT, n = 70). The effects of SLND on disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS) were assessed by Kaplan-Meier analysis and Cox regression models.
resultsDuring a median follow-up of about 35 months, 18.2% of patients died. Five-years OS, BCSS, and DFS rates in the RT and surgery + RT groups were 79.2% and 69.4% (P = 0.21), 82.2% and 79.4% (P = 0.29), and 56.1% and 53.1% (P = 0.70), respectively. In multivariable analysis, SLND didn't significantly impact these outcomes, a finding consistent across multiple subgroups. However, Estrogen receptor expression, the presence of vascular cancer emboli, and surgical approach differentially affected DFS, BCSS, and OS. Furthermore, patients with residual supraclavicular lymph node tumors post-surgery had lower DFS (43.7% vs. 73.2%) and OS (68.7% vs. 90.2%) rates compared with counterparts without residual lymph nodes. Residual supraclavicular lymph node tumor was an independent risk factor for DFS (HR = 4.191, 95%CI 1.755-10.007; p = 0.001) and OS (HR = 3.781, 95%CI 1.025-13.486; p = 0.046) in breast cancer patients with ISLNM.
conclusionsBreast cancer patients with synchronous ISLNM may not benefit from SLND. The clinical decision-making for ISLNM patients should be carefully considered. Prospective studies are needed to validate the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.